Charles Parker

2.4k total citations
21 papers, 397 citations indexed

About

Charles Parker is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Charles Parker has authored 21 papers receiving a total of 397 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 6 papers in Pulmonary and Respiratory Medicine and 5 papers in Immunology. Recurrent topics in Charles Parker's work include Porphyrin Metabolism and Disorders (5 papers), Complement system in diseases (5 papers) and Heme Oxygenase-1 and Carbon Monoxide (4 papers). Charles Parker is often cited by papers focused on Porphyrin Metabolism and Disorders (5 papers), Complement system in diseases (5 papers) and Heme Oxygenase-1 and Carbon Monoxide (4 papers). Charles Parker collaborates with scholars based in United States, United Kingdom and Italy. Charles Parker's co-authors include Brendan M. McGuire, Manish Thapar, Ashwani K. Singal, Lawrence Liu, Dervilla M. X. Donnelly, Jeffrey S. Millership, Manisha Balwani, D. Montgomery Bissell, Herbert L. Bonkovsky and Victoria Brown and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Charles Parker

19 papers receiving 388 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Charles Parker United States 8 170 96 69 60 52 21 397
Maciej Niedźwiecki Poland 11 76 0.4× 62 0.6× 39 0.6× 36 0.6× 15 0.3× 31 352
Laura Rubert Italy 13 81 0.5× 88 0.9× 65 0.9× 26 0.4× 27 0.5× 29 667
James Eales United Kingdom 13 276 1.6× 61 0.6× 37 0.5× 33 0.6× 40 0.8× 28 586
Tadaki Yasumura Japan 11 102 0.6× 24 0.3× 38 0.6× 38 0.6× 16 0.3× 27 420
Torben E. Jessen Denmark 10 142 0.8× 61 0.6× 39 0.6× 53 0.9× 4 0.1× 16 477
Victoria Hale United States 9 140 0.8× 156 1.6× 28 0.4× 128 2.1× 25 0.5× 17 516
Sally E. Ford Canada 11 96 0.6× 25 0.3× 18 0.3× 51 0.8× 8 0.2× 19 448
Silvana Anna Maria Urru Italy 10 86 0.5× 20 0.2× 25 0.4× 70 1.2× 18 0.3× 23 328
Carolyn R. Lew United States 14 162 1.0× 96 1.0× 43 0.6× 37 0.6× 2 0.0× 29 471

Countries citing papers authored by Charles Parker

Since Specialization
Citations

This map shows the geographic impact of Charles Parker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Parker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Parker more than expected).

Fields of papers citing papers by Charles Parker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles Parker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Parker. The network helps show where Charles Parker may publish in the future.

Co-authorship network of co-authors of Charles Parker

This figure shows the co-authorship network connecting the top 25 collaborators of Charles Parker. A scholar is included among the top collaborators of Charles Parker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles Parker. Charles Parker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bahaj, Waled, Bhavisha A. Patel, Ahmet Toprak, et al.. (2024). Ahemolytic PNH (white cell PNH): Clinical features and implications of a distinct phenotype of paroxysmal nocturnal haemoglobinuria. British Journal of Haematology. 204(5). 2121–2124. 2 indexed citations
2.
Markowski, Mark C., Yi Ren, Trevor J. Royce, et al.. (2024). Digital Pathology–based Artificial Intelligence Biomarker Validation in Metastatic Prostate Cancer. European Urology Oncology. 8(3). 755–762. 2 indexed citations
3.
4.
5.
Balwani, Manisha, Herbert L. Bonkovsky, Cynthia Levy, et al.. (2023). Dersimelagon in Erythropoietic Protoporphyrias. New England Journal of Medicine. 388(15). 1376–1385. 17 indexed citations
6.
Kuter, David J., Sioḃán Keel, Charles Parker, et al.. (2021). EIGHTEEN-MONTH INTERIM ANALYSIS OF EFFICACY AND SAFETY OF GIVOSIRAN, AN RNAI THERAPEUTIC FOR ACUTE HEPATIC PORPHYRIA, IN THE ENVISION OPEN LABEL EXTENSION. Hematology Transfusion and Cell Therapy. 43. S5–S6. 2 indexed citations
7.
Ventura, P., Herbert L. Bonkovsky, Laurent Gouya, et al.. (2021). Efficacy and safety of givosiran for acute hepatic porphyria: 24‐month interim analysis of the randomized phase 3 ENVISION study. Liver International. 42(1). 161–172. 61 indexed citations
8.
Singal, Ashwani K., Hetanshi Naik, Jessica Overbey, et al.. (2017). Porphyria Cutanea Tarda: Profile of 189 Patients from the Porphyrias Consortium in the United States. Gastroenterology. 152(5). S1156–S1156. 1 indexed citations
9.
Appleton, Lynda, Elizabeth Perkins, Charles Parker, et al.. (2014). The impact of prostate cancer on men's everyday life. European Journal of Cancer Care. 24(1). 71–84. 43 indexed citations
10.
Singal, Ashwani K., et al.. (2014). Liver transplantation in the management of porphyria. Hepatology. 60(3). 1082–1089. 90 indexed citations
11.
Parker, Charles, et al.. (2012). OP0106 Effect of BCX4208 add-on therapy to allopurinol 300 mg on plasma hypoxanthine and xanthine concentrations in gout patients. Annals of the Rheumatic Diseases. 71. 89–89. 5 indexed citations
12.
Parker, Charles. (2009). Eculizumab for paroxysmal nocturnal haemoglobinuria. The Lancet. 373(9665). 759–767. 103 indexed citations
13.
Wang, Xiaoli, Amanda J. LeBlanc, Mingjiang Xu, et al.. (2009). Clonal analyses define the relationships between chromosomal abnormalities and JAK2V617F in patients with Ph-negative myeloproliferative neoplasms. Experimental Hematology. 37(10). 1194–1200. 11 indexed citations
14.
Nilsson, Stefan, et al.. (2009). Alpharadin, a novel, highly targeted alpha pharmaceutical with a good safety profile for patients with CRPC and bone metastases: Combined safety analyses of phase I and II clinical trials. 2 indexed citations
15.
16.
Parker, Charles. (2008). Ask the Hematologist: How Do I Diagnose and Treat PNH?. The Hematologist. 5(3). 2 indexed citations
17.
Millership, Jeffrey S., Charles Parker, & Dervilla M. X. Donnelly. (2005). Ratio spectra derivative spectrophotometry for the determination of furosemide and spironolactone in a capsule formulation. Il Farmaco. 60(4). 333–338. 33 indexed citations
18.
Inoue, Norimitsu, Yuichi Endo, Jun‐ichi Nishimura, et al.. (2005). Clonal Expansion in Paroxysmal Nocturnal Hemoglobinuria (PNH): Expression of Mutant HMGA2 Suggests That PNH Is a Benign Tumor of the Bone Marrow.. Blood. 106(11). 3533–3533. 1 indexed citations
19.
Bono, Johann S. de, Joaquim Bellmunt, J.P. Droz, et al.. (2005). An open label, phase II, multicenter, study to evaluate the efficacy and safety of pertuzumab (P) in chemotherapy naïve patients (pts) with hormone refractory prostate cancer (HRPC). Journal of Clinical Oncology. 23(16_suppl). 4609–4609. 6 indexed citations
20.
Parker, Charles. (2000). Preface. Immunopharmacology. 49(1-2). 99–100. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maciej Niedźwiecki Breakdown of academic impact, for papers by Laura Rubert Breakdown of academic impact, for papers by James Eales Breakdown of academic impact, for papers by Tadaki Yasumura Breakdown of academic impact, for papers by Torben E. Jessen Breakdown of academic impact, for papers by Victoria Hale Breakdown of academic impact, for papers by Sally E. Ford Breakdown of academic impact, for papers by Silvana Anna Maria Urru Breakdown of academic impact, for papers by Carolyn R. Lew
Rankless by CCL
2026